Cabaletta Bio outlines 2026 strategic priorities for autoimmune therapy
Go back to Cabaletta Bio outlines 2026 strategic priorities for autoimmune therapy| (NASDAQ: CABA) | Delayed: 3.19 +0.09 (2.90%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.10 | 52 Week High | $ | |||
| Open | $3.04 | 52 Week Low | $ | |||
| Day High | $3.24 | P/E | N/A | |||
| Day Low | $2.95 | EPS | $ | |||
| Volume | 5,738,129 | |||||

